Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Milodistim

Drug Profile

Milodistim

Alternative Names: GM-CSF/IL-3; PIXY 321; Pixykine; Plasmid Immunex yeast 321

Latest Information Update: 23 Nov 1998

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Class Colony-stimulating factors
  • Mechanism of Action Granulocyte macrophage colony stimulating factor agonists; Interleukin 3 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chemotherapy-induced damage; Neutropenia; Thrombocytopenia

Most Recent Events

  • 23 Nov 1998 A clinical study has been added to the Haematological disorders therapeutic trials and pharmacokinetics sections
  • 29 Nov 1996 A study has been added to the Haematological disorders therapeutic trials and adverse effects sections
  • 11 Jul 1996 A clinical study has been added to the Cancer therapeutic trials and adverse events sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top